Karo Bio has recruited Dr Jens Kristensen as Head of Karo Bio’s clinical development activities. Jens Kristensen starts at Karo Bio in November 2005. His latest position was at AstraZeneca as Senior Clinical Research Physician.

Karo Bio has one project in clinical development and will in the coming years move additional projects into clinical development. Karo Bio therefore needs to develop its own resources to lead the clinical development activities. The recruitment of Jens Kristensen is a step in this direction. He will be a part of the Karo Bio Management Team as Head of Medicine and Vice President Clinical Development. Jens Kristensen took his Medical Exam at Odense University, Denmark, 1984 and achieved specialist competence in anaesthesiology and intensive care at Akademiska Sjukhuset in Uppsala 1990. Jens defended his thesis (Dr.Med.Sci.) in neuroscience at Uppsala University 1994. In 2001 Jens Kristensen achieved specialist competence in pharmaceutical medicine at the University of Basel. Through 16 years of clinical practise Jens Kristensen has had several positions e.g. as Head of Cardiac Surgery Intensive Care Unit at Odense University Hospital. Jens also played an important role in the build-up of a private hospital for cardiac surgery in Denmark. The last seven years Jens Kristensen has served within the pharmaceutical industry where he has achieved a broad competence from early to late phases of pharmaceutical development, both strategically and operationally. “Karo Bio’s research has high quality. The projects I have looked into are amongst the best I have seen in the industry. Now it is time to see if the concepts are valid in the clinic and I look forward to leading this work”, says Jens Kristensen. “I welcome Jens to Karo Bio and I am very happy to have him as a co-worker”, says Per Olof Wallström, President and CEO of Karo Bio. “I have previously had the privilege to work together with Jens in a corresponding position and I know that he will make important contributions to Karo Bio now when we take the next step in our development”. KARO BIO AB For further information, please contact: Per Olof Wallström, President & Chief Executive Officer Telephone: +46 8 608 60 20 Facts about Karo Bio Karo Bio is an innovative drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. Karo Bio is listed on the Stockholm stock exchange (Reuters: KARO.ST) since 1998. The Company has expanded from being a drug discovery company by adding in-housel development resources and competence for development of drugs to treat metabolic diseases. The Company has a strong project portfolio primarily targeting diseases such as diabetes, obesity, atherosclerosis and dyslipidemia. In addition, Karo Bio has two strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases. This press release is also available online at: www.karobio.com and www.waymaker.net.

About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.


Documents & Links